Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MK-0777

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia
BACKGROUND In a previous pilot study, MK-0777--a γ-aminobutyric acid (GABA)(A) α2/α3 partial agonist--was reported to improve… Expand
  • table 1
  • table 2
  • table 3
  • table 6
2011
2011
Pharmacological Enhancement of Cognition in Individuals with Schizophrenia
  • D. Lewis
  • Biological Psychiatry
  • 2011
    • Corpus ID: 26326511
w n “ i fi a f n d c t o t t T he principal pharmacological treatment for schizophrenia, antipsychotic medications, reduces the… Expand
Review
2011
Review
2011
GABA Neuron Alterations, Cortical Circuit Dysfunction and Cognitive Deficits in Schizophrenia
Schizophrenia is a brain disorder associated with cognitive deficits that severely affect the patients' capacity for daily… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2010
2010
Benzodiazepine Binding Site Occupancy by the Novel GABAA Receptor Subtype-Selective Drug 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b…
The GABAA receptor α2/α3 subtype-selective compound 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2008
Highly Cited
2008
Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia.
OBJECTIVE Deficits in working memory and cognitive control in schizophrenia are associated with impairments in prefrontal… Expand
  • figure 1
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE